

## FIRST TIME GENERIC APPROVAL

<b>Brand Name</b>	Insulin glargine
<b>Generic Name</b>	insulin glargine-yfgn
<b>Drug Manufacturer</b>	Mylan Specialty L.P.

### New Drug Approval

#### TYPE OF CLINICAL UPDATE

First Time Generic

#### FDA APPROVAL DATE

July 28, 2021

#### LAUNCH DATE

3<sup>rd</sup> Quarter of 2021

#### REVIEW DESIGNATION

N/A

#### TYPE OF REVIEW

Biologic License Application (BLA): 761201

#### DISPENSING RESTRICTIONS

N/A

### Overview

#### INDICATION FOR USE

Insulin glargine injection is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Limitations of Use: Not recommended for treating diabetic ketoacidosis.

#### MECHANISMS OF ACTION

The primary activity of insulin, including insulin glargine products, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis.

#### DOSE FORM AND STRENGTH

Injection: 100 units/mL (U-100) available as:

- 10 mL multiple-dose vial.
- 3 mL single-patient-use prefilled pen.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

## FIRST TIME GENERIC APPROVAL

### DOSE & ADMINISTRATION

- Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, prior insulin use.
- Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day.
- Do not dilute or mix with any other insulin or solution.
- Rotate injection sites to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.
- Closely monitor glucose when changing to insulin glargine products and during initial weeks thereafter.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.